Sibionics, an implantable medical devices developer, has secured product marketing authorisation from the UAE Ministry of Health and Prevention (MoHAP) for its GS1 Continuous Glucose Monitoring (CGM) System in the country.

The approval enables Sibionics to launch its GS1 CGM System in the UAE market, supporting the company’s global expansion plans.

The system received CE Mark approval in October last year.

The GS1 CGM System is designed to be fingerstick-free, factory-calibrated, and scanning-free system with a low mean absolute relative difference (MARD) value of 8.83% and a user-friendly interface.

It delivers real-time glucose data for 14 days, glucose alarms that can be customised, seamless data sharing, and an in-app AGP report that can be exported.

To enhance diabetes management, the GS1 CGM enables data sharing with friends and family and incorporates the ProView remote access platform. This allows healthcare providers to remotely monitor patients and offer timely medical interventions.

According to Sibionics, these key features are instrumental in optimising treatment plans and improving patient outcomes.

Alongside this approval, the medical devices developer has announced a partnership with Pharmaworld Store, appointing them as the exclusive distributor for the GS1 CGM System in the UAE.  

The collaboration will utilise Pharmaworld Store’s distribution network and market expertise to deliver the CGM System to healthcare providers and patients throughout the region.

Sibionics chief global strategy officer Patrick Nowlin said: “This approval from MoHAP is a testament to the quality and reliability of our GS1 CGM.

“We are thrilled to partner with Pharmaworld Store, whose deep understanding of the UAE healthcare market will be instrumental in bringing the GS1 to patients who need it most.”

Sibionics’ entry into the UAE market aims to enhance diabetes care and improve the quality of life for patients throughout the region.